Is Viking Therapeutics a good stock to buy?

Viking Therapeutics has received a consensus rating of Buy.

What does Viking therapeutics make?

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.

Will VKTX go up?

On average, Wall Street analysts predict that Viking Therapeutics’s share price could reach $13.00 by Jul 29, 2022. The average Viking Therapeutics stock price prediction forecasts a potential upside of 229.11% from the current VKTX share price of $3.95.

What is the outlook for Viking Therapeutics?

Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $16.75 with a high forecast of $20.00 and a low forecast of $14.00. The average price target represents a 339.63% change from the last price of $3.81.

What is VTVT Therapeutics?

About vTv Therapeutics Inc vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737.

Will Viking Therapeutics go up?

Is Rubius Therapeutics a buy?

Rubius Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Is VTVT a buy?

vTv Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

What is TTP399?

TTP399 is a liver-selective glucokinase (or GK) activator. GK acts as a key regulator of sugar levels in the body. When blood-sugar levels rise, activation of GK in the liver stimulates glucose utilization, which in turn lowers glucose levels in the blood.

Will Ruby stock go up?

Will Rubius Therapeutics stock price grow / rise / go up? Yes. The RUBY stock price can go up from 8.830 USD to 20.504 USD in one year.

Is Ruby a good stock?

The financial health and growth prospects of RUBY, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this stock lacks momentum and would be a lackluster choice for momentum investors.

What does vTv therapeutics do?

vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates.

Should you buy Viking Therapeutics stock?

Wall Street analysts have given Viking Therapeutics a “Buy” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viking Therapeutics wasn’t one of them.

Who is the CEO of Viking Energy Corporation?

Joining me today is Brian Lian, Viking’s president and CEO; and Greg Zante, Viking’s CFO. Today, we’ll provide an overview of our second-quarter 2021 financial results, as well as an update on recent progress and developments with our pipeline programs and operations.

When will Viking Therapeutics report Q2 earnings?

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2021, after the market close on Wednesday, July 28, 2021.

How much is a vktx stock worth?

One share of VKTX stock can currently be purchased for approximately $6.65. How much money does Viking Therapeutics make? Viking Therapeutics has a market capitalization of $519.96 million.